This study established the role of ARL4C in the initiation of premalignant lesions, tumor progression and development, and demonstrated the utility of ASO-1316 as a potential therapeutic agent for LC patients with ARL4C overexpression, regardless of mutation status. Here, ARL4C is linked to laryngotracheoesophageal cleft.